Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
4.400
+0.100 (2.33%)
Dec 20, 2024, 4:00 PM EST - Market closed
Clene Employees
As of December 31, 2023, Clene had 85 total employees, including 82 full-time and 3 part-time employees. The number of employees decreased by 1 or -1.16% compared to the previous year.
Employees
85
Change (1Y)
-1
Growth (1Y)
-1.16%
Revenue / Employee
$4,953
Profits / Employee
-$423,812
Market Cap
35.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85 | -1 | -1.16% |
| Dec 31, 2022 | 86 | -16 | -15.69% |
| Dec 31, 2021 | 102 | 28 | 37.84% |
| Dec 31, 2020 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Farmer Bros. Co. | 1,003 |
| ATA Creativity Global | 581 |
| Natural Alternatives International | 296 |
| China Liberal Education Holdings | 63 |
| United-Guardian | 25 |
| Barfresh Food Group | 10 |
| Safety Shot | 8 |
CLNN News
- 11 days ago - FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - GlobeNewsWire
- 2 months ago - Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - GlobeNewsWire
- 3 months ago - Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - GlobeNewsWire
- 4 months ago - Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 5 months ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 5 months ago - Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS - GlobeNewsWire